Symbiosis Pharmaceutical Services, a Contract Development and Manufacturing Organisation (CDMO) specialising in GMP sterile fill-finish manufacturing of injectable drug products, has appointed Joanne Anderson as its Chief Commercial Officer (CCO).

Anderson brings more than 25 years of experience in the pharmaceutical industry and international expertise to the role. Prior to joining Symbiosis, she served as global key account director at Recipharm and has previously worked with several global CDMOs. Her appointment also marks a return to Symbiosis after six years away from the organisation.

In her new role, Anderson will lead the company’s global commercial team and support the expansion of its market presence as demand for specialised GMP sterile fill-finish manufacturing continues to grow worldwide.

Commenting on her appointment, Anderson said that returning to Symbiosis felt like “coming home,” adding that she looks forward to leading the commercial team into new markets and exploring fresh growth opportunities.

The appointment comes at a time of strong momentum for the Stirling-based CDMO. The company has recently invested significantly in expanding its manufacturing capacity and successfully qualified a new commercial production facility aimed at meeting increasing global demand for sterile injectable drug product manufacturing.

Chief Executive Officer, Colin MacKay welcomed Anderson’s return, highlighting her deep understanding of client needs, the company’s technical capabilities and the broader pharmaceutical landscape. He noted that her leadership and global industry network will be instrumental in supporting Symbiosis’ commercial growth strategy.

Symbiosis plans to strengthen its footprint across North America, Europe and other international markets as it continues to position itself as a key manufacturing partner for innovative drug developers.